Nevis Brands announced that John Bell has resigned from its Board of Directors, effective November 2, 2026, and Scott McGregor has been appointed to fill the vacancy. McGregor brings extensive experience in corporate finance and capital markets, having led over 140 financing transactions and raised more than $2 billion in capital. His expertise is expected to support Nevis Brands' strategic growth initiatives. The company also granted McGregor 200,000 stock options as part of his appointment.
Nevis Brands' board changes provide context for readers following corporate developments. For readers following the Consumer Cyclical sector, here is Pluang's market snapshot as of Nov 02, 2026 19:11 WIB: Of 134 priced US Consumer Cyclical stocks tradable on Pluang, 81 rose and 28 fell today. Notable movers include CCL (Carnival Corp) at USD 29.30, up 1.67%, BIRD (Allbirds Inc) at USD 1.98, up 1.54%, and MBLY (MobilEye Global Inc) at USD 6.05, up 1.51%.
Callan JMB has received and will install a QuickStrip™ oral thin-film production line from Rapid Dose Therapeutics at its Texas facility, marking a key step in expanding its domestic pharmaceutical manufacturing. This new capability aims to produce f...
Known, a company developing accountability infrastructure for autonomous AI, announced that Edna Conway, former senior security executive at Microsoft and Cisco, has joined its Advisory Council. Conway brings extensive experience in cybersecurity and...
A SEON survey of 2,026 U.S. adults reveals that while 68% use AI agents weekly for personal tasks, half are uncomfortable letting AI handle credit card purchases. Only 15% would share financial info with AI, and 43% lack confidence in spotting fraudu...
Radiopharm Theranostics announced progress in its oncology radiopharmaceutical pipeline, including preparing for a pivotal Phase 3 imaging trial of RAD101 for recurrent brain metastases after a successful FDA End-of-Phase 2 meeting. The company also ...
UroGen Pharma has dosed the first patient in a Phase 1 trial testing UGN-501, a next-generation oncolytic virus for non-muscle invasive bladder cancer (NMIBC). The trial aims to evaluate the safety and tolerability of UGN-501 administered directly in...
